97 related articles for article (PubMed ID: 3106247)
1. The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas.
Holte H; Davies CD; Kvaløy S; Smeland EB; Foss-Abrahamsen A; Kaalhus O; Marton PF; Godal T
Int J Cancer; 1987 May; 39(5):590-4. PubMed ID: 3106247
[TBL] [Abstract][Full Text] [Related]
2. Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma.
Holte H; de Lange Davies C; Beiske K; Stokke T; Marton PF; Smeland EB; Høie J; Kvaløy S
Int J Cancer; 1989 Dec; 44(6):975-80. PubMed ID: 2606582
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma.
Salter DM; Krajewski AS; Sheehan T; Turner G; Cuthbert RJ; Mclean A
J Pathol; 1989 Nov; 159(3):211-20. PubMed ID: 2593045
[TBL] [Abstract][Full Text] [Related]
4. Expression of the activation antigen, 4F2, by non-Hodgkin's lymphomas of B-cell phenotype.
Lewandrowski KB; Medeiros LJ; Harris NL
Cancer; 1990 Sep; 66(6):1158-64. PubMed ID: 1698116
[TBL] [Abstract][Full Text] [Related]
5. Idiotypic immunoglobulin secretion by human B cell non-Hodgkin's lymphomas is related to the expression of the interleukin-2 receptor.
Vyth-Dreese FA; Dellemijn TA; Hekman A; Melief CJ
Leukemia; 1988 Apr; 2(4):231-5. PubMed ID: 3129622
[TBL] [Abstract][Full Text] [Related]
6. The cellular content of non Hodgkin lymphomas: a comprehensive analysis using monoclonal antibodies and other surface marker techniques.
Habeshaw JA; Bailey D; Stansfeld AG; Greaves MF
Br J Cancer; 1983 Mar; 47(3):327-51. PubMed ID: 6338896
[TBL] [Abstract][Full Text] [Related]
7. Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets.
Beiske K; Clark EA; Holte H; Ledbetter JA; Smeland EB; Godal T
Int J Cancer; 1988 Oct; 42(4):521-8. PubMed ID: 2459071
[TBL] [Abstract][Full Text] [Related]
8. Immunologic markers in non-Hodgkin's lymphoma.
Freedman AS; Nadler LM
Hematol Oncol Clin North Am; 1991 Oct; 5(5):871-89. PubMed ID: 1938759
[TBL] [Abstract][Full Text] [Related]
9. Dual parameter flow cytometric analysis of DNA content, activation antigen expression, and T cell subset proliferation in the human mixed lymphocyte reaction.
Williams JM; Loertscher R; Cotner T; Reddish M; Shapiro HM; Carpenter CB; Strominger JL; Strom TB
J Immunol; 1984 May; 132(5):2330-7. PubMed ID: 6325537
[TBL] [Abstract][Full Text] [Related]
10. Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas.
Kvaløy S; Langholm R; Kaalhus O; Michaelsen T; Funderud S; Foss Abrahamsen A; Godal T
Int J Cancer; 1984 Feb; 33(2):173-7. PubMed ID: 6319299
[TBL] [Abstract][Full Text] [Related]
11. Expression of B cell activation antigens on normal and malignant B cells.
Freedman AS; Boyd AW; Berrebi A; Horowitz JC; Levy DN; Rosen KJ; Daley J; Slaughenhoupt B; Levine H; Nadler LM
Leukemia; 1987 Jan; 1(1):9-15. PubMed ID: 3118102
[TBL] [Abstract][Full Text] [Related]
12. Characterization of malignant and non-neoplastic cell phenotypes in highly malignant non-Hodgkin lymphomas.
Porwit-Ksiazek A; Christensson B; Lindemalm C; Mellstedt H; Tribukait B; Biberfeld G; Biberfeld P
Int J Cancer; 1983 Dec; 32(6):667-74. PubMed ID: 6317576
[TBL] [Abstract][Full Text] [Related]
13. Transferrin receptor expression by non-Hodgkin's lymphomas. Correlation with morphologic grade and survival.
Medeiros LJ; Picker LJ; Horning SJ; Warnke RA
Cancer; 1988 May; 61(9):1844-51. PubMed ID: 3355978
[TBL] [Abstract][Full Text] [Related]
14. Activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma.
Salter DM; Krajewski AS; Cunningham S
J Pathol; 1988 Mar; 154(3):209-22. PubMed ID: 3280770
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
17. [Non-Hodgkin's lymphoma: correlation of cell surface marker phenotype with clinical features and prognosis].
Okabe K; Toki H; Kimura Y; Fujii M; Kiura K; Moriwaki S
Gan To Kagaku Ryoho; 1986 Oct; 13(10):2960-4. PubMed ID: 3490224
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of cell activation markers after stimulation of resting human B lymphocytes.
Kehrl JH; Muraguchi A; Fauci AS
J Immunol; 1984 Jun; 132(6):2857-61. PubMed ID: 6427329
[TBL] [Abstract][Full Text] [Related]
19. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
20. Low grade malignant non-Hodgkin's lymphomas and peripheral pleomorphic T-cell lymphomas in childhood--a BFM study group report.
Bucsky P; Feller AC; Reiter A; Beck J; Bertram U; Eschenbach C; Gerein V; Lakomek M; Stollmann B; Tausch W
Klin Padiatr; 1990; 202(4):258-61. PubMed ID: 2203939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
